[go: up one dir, main page]

CY1122773T1 - Χρηση (1r,5s)-(+)-1-(ναφθαλεν-2-υλ)-3-αζαδικυκλο{3.1.0.}εξανιου στην αγωγη παθησεων επηρεαζομενων απο νευροδιαβιβαστες μονοαμινης - Google Patents

Χρηση (1r,5s)-(+)-1-(ναφθαλεν-2-υλ)-3-αζαδικυκλο{3.1.0.}εξανιου στην αγωγη παθησεων επηρεαζομενων απο νευροδιαβιβαστες μονοαμινης

Info

Publication number
CY1122773T1
CY1122773T1 CY20201100241T CY201100241T CY1122773T1 CY 1122773 T1 CY1122773 T1 CY 1122773T1 CY 20201100241 T CY20201100241 T CY 20201100241T CY 201100241 T CY201100241 T CY 201100241T CY 1122773 T1 CY1122773 T1 CY 1122773T1
Authority
CY
Cyprus
Prior art keywords
naphthalen
hexane
treatment
azadicyclo
monoamine neurotransmitters
Prior art date
Application number
CY20201100241T
Other languages
English (en)
Inventor
Anthony Alexander Mckinney
Frank Bymaster
Original Assignee
Otsuka America Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka America Pharmaceutical, Inc. filed Critical Otsuka America Pharmaceutical, Inc.
Publication of CY1122773T1 publication Critical patent/CY1122773T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στο (1R,5S)-(+)-1-(ναφθαλεν-2-υλ)-3-αζαδικυκλο[3.1.0]εξάνιο και σε φαρμακευτικές συνθέσεις αυτού, και σε μεθόδους που χρησιμοποιούν τη χρήση τους στην αγωγή παθήσεων που επηρεάζονται από νευροδιαβιβαστές μονοαμίνης, συμπεριλαμβανομένων της ΔΕΠΥ και της κατάχρησης ουσιών.
CY20201100241T 2011-07-30 2020-03-17 Χρηση (1r,5s)-(+)-1-(ναφθαλεν-2-υλ)-3-αζαδικυκλο{3.1.0.}εξανιου στην αγωγη παθησεων επηρεαζομενων απο νευροδιαβιβαστες μονοαμινης CY1122773T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161574231P 2011-07-30 2011-07-30
US201113334066A 2011-12-22 2011-12-22
US201213528940A 2012-06-21 2012-06-21
PCT/US2012/000335 WO2013019271A1 (en) 2011-07-30 2012-07-27 Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters

Publications (1)

Publication Number Publication Date
CY1122773T1 true CY1122773T1 (el) 2021-05-05

Family

ID=47629575

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100241T CY1122773T1 (el) 2011-07-30 2020-03-17 Χρηση (1r,5s)-(+)-1-(ναφθαλεν-2-υλ)-3-αζαδικυκλο{3.1.0.}εξανιου στην αγωγη παθησεων επηρεαζομενων απο νευροδιαβιβαστες μονοαμινης

Country Status (12)

Country Link
EP (1) EP2819516B1 (el)
CA (1) CA2843847C (el)
CY (1) CY1122773T1 (el)
DK (1) DK2819516T3 (el)
ES (1) ES2779032T3 (el)
HR (1) HRP20200424T1 (el)
HU (1) HUE048715T2 (el)
LT (1) LT2819516T (el)
PL (1) PL2819516T3 (el)
PT (1) PT2819516T (el)
SI (1) SI2819516T1 (el)
WO (1) WO2013019271A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101272781A (zh) 2005-07-27 2008-09-24 多夫药品公司 新的1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20160303077A1 (en) * 2013-12-09 2016-10-20 Neurovance, Inc. Novel compositions
CN107921021A (zh) * 2015-06-17 2018-04-17 大塚制药美国公司 结晶化合物
WO2018002926A1 (en) 2016-06-28 2018-01-04 Seach Sarid Ltd. A dosage form for vaporization and smoking
WO2018119291A1 (en) * 2016-12-21 2018-06-28 Otsuka America Pharmaceutical, Inc. Synthetic methods
CA3264158A1 (en) 2022-09-02 2024-03-07 Otsuka Pharmaceutical Co., Ltd. 1-(NAPHTALENE-2-YL)-3-AZABICYCLO[3.1.0]HEXANE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
WO2025183181A1 (en) * 2024-02-28 2025-09-04 Otsuka Pharmaceutical Co., Ltd. Use of centanafadine in treatment of adhd symptoms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
CN101272781A (zh) * 2005-07-27 2008-09-24 多夫药品公司 新的1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途

Also Published As

Publication number Publication date
LT2819516T (lt) 2020-05-25
WO2013019271A1 (en) 2013-02-07
ES2779032T3 (es) 2020-08-13
EP2819516B1 (en) 2019-12-25
CA2843847A1 (en) 2013-02-07
DK2819516T3 (da) 2020-03-16
SI2819516T1 (sl) 2020-07-31
HUE048715T2 (hu) 2020-09-28
PT2819516T (pt) 2020-03-25
EP2819516A4 (en) 2016-01-20
PL2819516T3 (pl) 2020-08-10
CA2843847C (en) 2021-05-18
HRP20200424T1 (hr) 2020-09-04
EP2819516A1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
CY1122773T1 (el) Χρηση (1r,5s)-(+)-1-(ναφθαλεν-2-υλ)-3-αζαδικυκλο{3.1.0.}εξανιου στην αγωγη παθησεων επηρεαζομενων απο νευροδιαβιβαστες μονοαμινης
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1125436T1 (el) Αναστολεις dna-pk
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1120807T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
EA201490420A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
CY1116578T1 (el) Αναστολεις της bromodomain και χρησεις αυτων
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
BR112015018284A2 (pt) amidas como moduladores de canais de sódio
CY1112813T1 (el) 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201490540A1 (ru) Соединения и композиции в качестве ингибиторов с-kit киназы
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
HUE050319T2 (hu) Kompozíciók és eljárások alkoholfogyasztással kapcsolatos rendellenességek, fájdalom és más betegségek kezelésére
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201590562A1 (ru) Бензамиды